Malirid DS (Primaquine) Tablet
$77.00
Malirid DS (Primaquine) Tablet is a powerful antimalarial used to eliminate Plasmodium vivax and Plasmodium ovale infections from the liver, preventing relapse. It works by destroying dormant parasites that standard treatments may leave behind, offering a complete and long-lasting cure. Malirid DS is especially effective in preventing future outbreaks after the initial infection has cleared. Take it exactly as prescribed to ensure total parasite elimination and long-term protection from malaria recurrence.
Quantity
USES OF MALIRID TABLET
- Malaria
BENEFITS OF MALIRID TABLET
In Malaria
Malirid-DS Tablet is an antimalarial medicine and is used to treat malaria, a serious or life-threatening illness that is spread by a parasite that enters the human body by the bite of infected mosquitoes. It kills the infection-causing parasite and stops the further spread of the infection. Take it only as prescribed and refrain from taking any other medicines along with this medicine (unless advised by the doctor) as they may affect the absorption of this medicine. Do not use this medicine for treating any other condition without consulting your doctor.
SIDE EFFECTS OF MALIRID TABLET
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Malirid
- Rash
- Vomiting
- Headache
- Dizziness
- Hives
- Stomach pain
- Nausea
- Abdominal pain
- Itching
- Heartburn
- Gastrointestinal discomfort
- Upper abdominal pain
HOW TO USE MALIRID TABLET
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Malirid-DS Tablet is to be taken with food.
HOW MALIRID TABLET WORKS
Malirid-DS Tablet is an antiparasitic medication that treats malaria. It works by increasing the levels of haeme in the blood, a substance toxic to the malarial parasite. This kills the parasite and stops the infection from spreading.
